Mabion (WAR:MAB) Total Equity: zł39.09 Mil (As of Mar. 2026)


WAR:MAB Mabion SA WAR:MAB
30 GF Score
Price zł7.40
GF Value zł2.10
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Mabion Total Equity?

Mabion WAR:MAB -0.80% 30 Total Equity is zł39.09 Mil as of Mar. 2026. GuruFocus rates WAR:MAB with a GF Score™ of 30/100 and a GF Value™ of zł2.10 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Mabion's total equity for the quarter that ended in Mar. 2026 was zł39.09 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Mabion Total Equity Historical Data

* Premium members only.

The historical data trend for Mabion's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mabion Total Equity Chart

Mabion Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 53.31 76.51 117.78 111.44 48.83

Mabion Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 96.32 80.77 70.02 48.83 39.09
WAR:MAB
30GF Score
Mabion SA WAR:MAB
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mabion Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Mabion's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=110.433-61.605
=48.83

Mabion's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=109.846-70.756
=39.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of zł39.09 Mil mean?
Mabion (WAR:MAB) has a Total Equity of zł39.09 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Mabion and its competitors.
Is Mabion's Total Equity too high?
Mabion's current Total Equity is zł39.09 Mil. Overall, Mabion has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Mabion's Total Equity compare to VRTX and REGN?
Mabion's Total Equity of zł39.09 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Mabion and its competitors. Mabion's current Total Equity is zł39.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mabion stock overvalued right now?
Based on GuruFocus' analysis, Mabion (WAR:MAB) is currently considered Significantly Overvalued. The stock's GF Value™ is zł2.10, compared to a current price of zł7.40 — trading 252.4% above its estimated fair value. The current Total Equity is zł39.09 Mil. Mabion's overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Mabion (WAR:MAB), the current Total Equity is zł39.09 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mabion (WAR:MAB) Overvalued in 2026?

Based on GuruFocus' analysis, Mabion stock appears to be overvalued. The current stock price of zł7.40 is trading 252.4% above its estimated GF Value™ of zł2.10. GuruFocus considers Mabion to be Significantly Overvalued.

Key valuation signals for WAR:MAB:

  • Total Equity: zł39.09 Mil
  • GF Value™: zł2.10 vs. price of zł7.40 (252.4% above fair value)
  • GF Score™: 30/100 with 4 warning signs

No single metric tells the full story. See the WAR:MAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mabion Business Description

Other Exchanges 272:Germany
Address ul. Gen. Mariana Langiewicza 60, Konstantynow Lodzki, POL, 95-050
Mabion SA is a Polish biotechnology company focused on developing and launching modern biotechnology drugs based on monoclonal antibody technology. The drugs developed by the company are targeted treatments, characterized by the drug's ability to recognize the factor causing cancer and interact with this factor only. The company is working on the development of its main priority drug, referred to as the MabionCD20 drug. The therapeutic uses of MabionCD20 are for Non-Hodgkin's lymphoma, Leukemia, and Rheumatoid Arthritis.
30GF Score

Get the complete analysis for WAR:MAB

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł7.40
Price
zł2.10
GF Value